Translate and validate the MQOL quality-of-life questionnaire into French for people with meningioma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational project will produce a French translation of the MQOL self-questionnaire and perform linguistic validation. In a second phase, the translated MQOL will be tested in 50 adults with confirmed intracranial meningioma and compared with EQ-5D, Karnofsky Performance Status, and FACT-Br to examine reliability and internal consistency. Eligible participants are French-speaking adults able to give informed consent; pregnant, legally restricted, or psychiatric inpatients are excluded. The work will be conducted at GHU Paris - Psychiatrie & Neurosciences (Centre Hospitalier Sainte-Anne) in Paris.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient aged 18 years or older
* Diagnosis of intracranial meningioma confirmed by imaging or surgery

Exclusion Criteria:

* Pregnant or breastfeeding women (Article L1121-5)
* Patients deprived of liberty by judicial or administrative decision, as well as individuals undergoing psychiatric care (Article L1121-6)
* Patients not fluent in French or with poor understanding of the language
* Inability to refuse participation in the study

Where it's running

• GHU Paris -Psychiatrie & Neurosciences
  Paris, France Recruiting

Study contacts

• Study coordinator: Viviane AWASSI
• Email: v.awassi@ghu-paris.fr
• Phone: 01.45.65.84.86

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combination therapy with IN10018 and dalpiciclib for progressive meningioma

  This phase 1 study tests whether taking IN10018 with dalpiciclib is safe and tolerable in adults with growing meningiomas to see if the combo can help control the tumor.

  Recruiting Phase 1 Capital Medical University · Beijing, Beijing Municipality and 1 other locations · NCT07652762

• JZP3507 (ONC206) for recurrent Grade 2/3 meningioma

  A pill-based therapy (JZP3507) is being tested to see if it can help adults with recurrent grade 2 or 3 meningioma who have not benefited from standard treatments.

  Recruiting at 6 sites Phase 2 Jazz Pharmaceuticals · San Francisco, California and 7 other locations · NCT07533942

• Panitumumab-IRDye800 for guiding brain tumor surgery

  A tiny dose of panitumumab-IRDye800 is tested to see if it helps visualize brain tumors during surgery in adults.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07493447

• Zanzalintinib for recurrent or progressive meningioma

  This trial tests whether zanzalintinib can help people whose meningioma has come back or kept growing after standard treatments.

  Recruiting at 20 sites Phase 2 Exelixis · Birmingham, Alabama and 19 other locations · NCT07428616

• Meningioma: How social factors and personal risks relate to health outcomes

  This study tests whether social and personal risk factors help explain differences in health outcomes for adults with meningioma.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07418775

• Skin closure after brain tumor surgery: running absorbable versus interrupted non-absorbable sutures

  This will test whether absorbable running intradermal sutures or non-absorbable interrupted transdermal sutures produce better wound healing after craniotomy in adults with supratentorial brain tumors.

  Recruiting Medical University of Warsaw · Warsaw, Masovian Voivodeship · NCT07413796

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.